Direkt zum Inhalt
Merck
  • Purification, enzymatic activity and inhibitor discovery for recombinant human carbonic anhydrase XIV.

Purification, enzymatic activity and inhibitor discovery for recombinant human carbonic anhydrase XIV.

Journal of biotechnology (2016-10-25)
Vaida Juozapaitienė, Brigita Bartkutė, Vilma Michailovienė, Audrius Zakšauskas, Lina Baranauskienė, Sandra Satkūnė, Daumantas Matulis
ZUSAMMENFASSUNG

Human carbonic anhydrase XIV (CA XIV), a transmembrane protein, highly expressed in the central nervous system, is difficult to recombinantly express and purify in large scale for the measurements of inhibitor binding and drug design. CA XIV belongs to the family of twelve catalytically active CA isoforms in the human body. Disorders in the expression of CA XIV cause serious diseases and CA XIV has been described as a possible drug target for the treatment of epilepsy, some retinopathies, and skin tumors. In this study, the effect of different promoters, E. coli strains, and the length of recombinant CA XIV protein construct were analyzed for the production CA XIV in large scale by using affinity purification. Active site titration by inhibitors and the isothermal titration calorimery revealed over 96% purity of the protein. Enzymatic activity of the purified CA XIV was determined by following the CO

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Trifluormethansulfonamid, 95%
Sigma-Aldrich
Dorzolamide, ≥98% (HPLC)